| Nov-21-18 09:02AM | Clovis' (CLVS) Rubraca Gets Another US Patent, Shares Up Zacks |
| 08:58AM | TESARO Shares Rally on Rumors of Potential Acquisition Offer Zacks |
| 08:16AM | Can Deal Interest Help Tesaro Recover? Motley Fool |
| Nov-20-18 08:12AM | Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails Zacks |
| 07:00AM | Today's Research Reports on Trending Tickers: AstraZeneca and AbbVie ACCESSWIRE |
| Nov-19-18 02:33PM | Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta Zacks |
| 09:49AM | AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down Zacks |
| Nov-16-18 09:39AM | Stocks Slide At Open; This Dow Jones Name Bucks Chip Sell Off Investor's Business Daily |
| 08:35AM | Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings Zacks |
| 08:31AM | AstraZeneca Shows It Can Still Take Some Knocks Bloomberg |
| 08:09AM | Is AstraZeneca PLC (LON:AZN) Excessively Paying Its CEO? Simply Wall St. |
| 03:08AM | AstraZenecas Lung Cancer Trial Fails to Meet Main Goal Bloomberg |
| 02:43AM | [$$] AstraZeneca Mystic lung cancer trial fails to deliver results Financial Times |
| Nov-14-18 03:22PM | AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi Zacks |
| 10:28AM | Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA Zacks |
| 05:45AM | AstraZeneca (AZN): Are Hedge Funds Right to be Bearish? Insider Monkey |
| Nov-13-18 04:45PM | This Recent Big Pharma Breakout Spiked Again On A $1.5 Billion Deal Investor's Business Daily |
| 01:41PM | AstraZeneca's Lynparza Gets Priority Review in 1st Line Use Zacks |
| 10:47AM | $1.5B deal: AstraZeneca sells U.S. rights to respiratory medicine American City Business Journals |
| 05:05AM | AstraZeneca Keeps Pruning Drugs in $1.5 Billion Sale to Sobi Bloomberg |
| 04:36AM | [$$] European Corporate Roundup The Wall Street Journal |
| 03:33AM | Sobi buys rights to AstraZeneca infant drug for $1.5 bln upfront Reuters |
| 02:35AM | AstraZeneca sells infant drug rights to Sobi for $1.5 bln upfront Reuters |
| Nov-12-18 06:55AM | US FDA Accepts Regulatory Submission For LYNPARZA (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-mutated Advanced Ovarian Cancer and Grants Priority Review Business Wire |
| Nov-10-18 04:45PM | FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial Business Wire |
| 04:45PM | AstraZeneca's diabetes drug curbs heart failure, kidney risks Reuters |
| 04:45AM | [$$] AstraZeneca diabetes drug cuts complications Financial Times |
| Nov-09-18 07:31AM | Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug Zacks |
| 07:00AM | Today's Research Reports on Trending Tickers: AstraZeneca and Bristol-Myers Squibb ACCESSWIRE |
| 01:32AM | [$$] Opinion today: Europes plan for Donald Trump Financial Times |
| Nov-08-18 04:14PM | AstraZeneca Breaks Out As CEO Predicts 'Sustained Growth' Streak Investor's Business Daily |
| 03:37PM | Edited Transcript of AZN.L earnings conference call or presentation 8-Nov-18 12:00pm GMT Thomson Reuters StreetEvents |
| 12:20PM | AstraZeneca lifts FTSE as U.S. midterm rally fades Reuters |
| 11:35AM | AstraZeneca chief says the US drugs market is under pressure and changes are coming CNBC |
| 10:38AM | AstraZeneca sees years of growth as drug sales turn corner Reuters |
| 10:38AM | AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales Zacks |
| 10:36AM | Astrazeneca: 3Q Earnings Snapshot Associated Press |
| 10:33AM | AstraZeneca sees years of growth as drug sales turn corner Reuters |
| 06:24AM | [$$] AstraZeneca 3Q Sales Increased on New Drug Performance The Wall Street Journal |
| 04:42AM | [$$] European Corporate Roundup The Wall Street Journal |
| 03:18AM | AstraZeneca has finally delivered its four-year objective... CNBC Videos |
| 02:26AM | AstraZeneca returns to sales growth, led by cancer medicines CNBC |
| 02:14AM | AstraZeneca returns to sales growth, led by cancer medicines Reuters |
| 12:01AM | [$$] AstraZeneca: back from the abyss Financial Times |
| Nov-07-18 11:09PM | [$$] AstraZeneca shares surge as new drugs spark hope of growth Financial Times |
| 04:00PM | Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer GlobeNewswire |
| 01:29PM | Astrazeneca Q3 Earnings Preview Benzinga |
| Nov-06-18 05:48PM | Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript Motley Fool |
| 09:30AM | BMY vs. AZN: Which Stock Is the Better Value Option? Zacks |
| 09:12AM | Cheplapharm Arzneimittel GmbH -- Moody's affirms Cheplapharm's B1 CFR, assigns B1 to term loan add-on, stable outlook Moody's |
| 07:00AM | Today's Research Reports on Trending Tickers: AbbVie and AstraZeneca ACCESSWIRE |
| 04:44AM | [$$] European Corporate Roundup The Wall Street Journal |
| 03:18AM | [$$] AstraZeneca sells trio of respiratory drugs for $350m Financial Times |
| 03:03AM | AstraZeneca sells older asthma, rhinitis drugs for $350 million Reuters |
| 02:44AM | AstraZeneca sells older asthma, rhinitis drugs for $350 mln Reuters |
| Nov-02-18 08:09AM | Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus Zacks |
| Nov-01-18 01:59PM | European businesses demand urgent Brexit deal after meeting May Reuters |
| 07:00AM | The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018 Business Wire |
| Oct-30-18 05:31PM | AstraZeneca sells some rights to Nexium, Vimovo to Grunenthal Reuters |
| 04:53AM | [$$] European Corporate Roundup The Wall Street Journal |
| 03:30AM | [$$] AstraZeneca to Sell Drugs Rights for $815M The Wall Street Journal |
| Oct-26-18 11:39AM | Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO Zacks |
| 09:00AM | Report: Exploring Fundamental Drivers Behind Manulife Financial, Baozun, AstraZeneca, Insight Enterprises, Albireo Pharma, and Mobile TeleSystems OJSC New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
| Oct-25-18 08:00AM | Today's Research Reports on Trending Tickers: AstraZeneca and Eli Lilly and Company ACCESSWIRE |
| 03:29AM | [$$] The London Report: dollar earners buoy FTSE 100 Financial Times |
| Oct-24-18 06:49PM | Here's Why Tesaro Inc. Dropped 13.8% Today Motley Fool |
| Oct-23-18 08:08PM | [$$] AstraZeneca Adds Cancer Drugs to Pipeline with Innate Pharma Deal The Wall Street Journal |
| 01:03PM | AstraZeneca dips, Harley-Davidson plummets, Johnson & Johnson down slightly Yahoo Finance |
| 11:13AM | AstraZeneca, Harley-Davidson and Johnson and Johnson are the Yahoo Finance charts of the day. Yahoo Finance Video |
| 10:01AM | [$$] AstraZeneca Adds Cancer Drugs to Pipeline The Wall Street Journal |
| 04:09AM | AstraZeneca digs deeper into cancer with Innate stake Reuters |
| 01:48AM | AstraZeneca to buy 9.8 percent stake in France's Innate Pharma Reuters |
| 12:21AM | [$$] AstraZeneca strengthens cancer focus with Innate deal Financial Times |
| Oct-22-18 04:23PM | Why Tesaro, Inc. Is Tanking Today Motley Fool |
| 01:06PM | Here's Why Clovis Oncology Dropped as Much as 21.2% Today Motley Fool |
| 07:00AM | AstraZeneca to Present New Data Demonstrating Breadth of Research Portfolio in Renal Disease at ASN Kidney Week 2018 Business Wire |
| Oct-21-18 10:33AM | Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer Business Wire |
| 10:30AM | AstraZeneca's Lynparza shown to put brakes on ovarian cancer Reuters |
| Oct-20-18 11:29PM | [$$] AstraZeneca gets cancer trial boost for Lynparza drug Financial Times |
| Oct-19-18 10:01AM | The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke Zacks |
| Oct-17-18 05:03PM | 2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report Motley Fool |
| Oct-16-18 05:16PM | Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional Yahoo Finance |
| 03:48PM | AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status Zacks |
| 10:54AM | Drug commercials you see on TV may be overhauled Yahoo Finance Video |
| Oct-15-18 03:57PM | May says Irish backstop can't derail deadlocked Brexit talks Reuters |
| 12:18PM | AstraZeneca will keep UK investment freeze if no Brexit clarity Reuters |
| 12:04PM | AstraZeneca will keep UK investment freeze if no Brexit clarity Reuters |
| 10:10AM | AstraZeneca halts UK investments due to Brexit uncertainties The Telegraph |
| 09:46AM | AstraZeneca halts UK investments due to Brexit uncertainties - Le Monde Reuters |
| 09:32AM | Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit Reuters |
| Oct-12-18 10:12AM | 3 Large-Cap Pharma Stocks Performing Better Than Industry Zacks |
| 10:04AM | J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion Zacks |
| Oct-11-18 05:16PM | Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts Zacks |
| 09:01AM | 3 Dividend Stocks That Pay You Better Than Pepsi Does Motley Fool |
| Oct-09-18 02:34PM | Top Research Reports for JPMorgan, American Express & FedEx Zacks |
| Oct-03-18 12:20AM | [$$] Nobel chemistry prize given for work that harnessed evolution Financial Times |
| Oct-02-18 11:00AM | 2 Stocks That Can Safely Double Your Money Motley Fool |
| Oct-01-18 02:56PM | Roche Gets FDA Approval for New Formulation of Asthma Drug Zacks |
| Sep-28-18 10:07AM | Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs Zacks |
| 08:00AM | Report: Developing Opportunities within AstraZeneca, Manulife Financial, Infosys, Novartis AG, Black Hills, and Shell Midstream Partners Future Expectations, Projections Moving into 2018 GlobeNewswire |
|
|
|
| AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. |
